Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis

Rosanna Di Paola, Emanuela Esposito, Emanuela Mazzon, Luisa Riccardi, Rocco Caminiti, Roberto Dal Toso, Giovanna Pressi, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of the present study was to examine the effects of phenylpropanoid glycoside, teupolioside, biotechnologically produced by IRBN22 Ajuga reptans cell line, in rats subjected to experimental colitis. Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulfonic acid (DNBS). Teupolioside was administered daily orally (0.2 or 2 mg kg-1). On Day 4, animals were sacrificed and tissues were taken for histological and biochemical analysis. Four days after DNBS administration, colon TNF-α and IL-1β productions were increased, associated with colon damage. Neutrophil infiltration, by myeloperoxidase activity, in the mucosa was associated with up-regulation of ICAM-1 and P-selectin and high levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed an intense staining in the inflamed colon. Biochemical methods and zymography were used to analyze MMP-9 and -2 activities in colon tissues from DNBS-injured rats. Treatment with teupolioside significantly reduced the appearance of diarrhoea and the loss of body weight. This was associated with a remarkable amelioration in the disruption of the colonic architecture and a significant reduction in colonic myeloperoxidase activity and malondialdehyde levels. Teupolioside also reduced the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PARP immunoreactivity in the colon and reduced the up-regulation of ICAM-1 and the expression of P-selectin. Therefore, teupolioside also reduced proMMP-9 and -2 activity induced in the colon by DNBS administration. The results of this study suggested that administration of teupolioside may be beneficial for treatment of inflammatory bowel disease.

Original languageEnglish
Pages (from-to)845-857
Number of pages13
JournalBiochemical Pharmacology
Volume77
Issue number5
DOIs
Publication statusPublished - Mar 1 2009

Fingerprint

Ajuga
Plant Cells
Colitis
Glycosides
Dinitrobenzenes
Rodentia
Colon
Sulfonic Acids
Cell Line
Rats
P-Selectin
Poly(ADP-ribose) Polymerases
Intercellular Adhesion Molecule-1
Malondialdehyde
Peroxidase
Up-Regulation
Tissue
Neutrophil Infiltration
Matrix Metalloproteinases
Interleukin-1

Keywords

  • Adhesion molecules
  • Colitis
  • MMP9 (matrix metallopeptidase 9)
  • Teupolioside

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis. / Di Paola, Rosanna; Esposito, Emanuela; Mazzon, Emanuela; Riccardi, Luisa; Caminiti, Rocco; Dal Toso, Roberto; Pressi, Giovanna; Cuzzocrea, Salvatore.

In: Biochemical Pharmacology, Vol. 77, No. 5, 01.03.2009, p. 845-857.

Research output: Contribution to journalArticle

Di Paola, Rosanna ; Esposito, Emanuela ; Mazzon, Emanuela ; Riccardi, Luisa ; Caminiti, Rocco ; Dal Toso, Roberto ; Pressi, Giovanna ; Cuzzocrea, Salvatore. / Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis. In: Biochemical Pharmacology. 2009 ; Vol. 77, No. 5. pp. 845-857.
@article{49aaeec7e2694f56b106b9ac463c8589,
title = "Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis",
abstract = "The aim of the present study was to examine the effects of phenylpropanoid glycoside, teupolioside, biotechnologically produced by IRBN22 Ajuga reptans cell line, in rats subjected to experimental colitis. Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulfonic acid (DNBS). Teupolioside was administered daily orally (0.2 or 2 mg kg-1). On Day 4, animals were sacrificed and tissues were taken for histological and biochemical analysis. Four days after DNBS administration, colon TNF-α and IL-1β productions were increased, associated with colon damage. Neutrophil infiltration, by myeloperoxidase activity, in the mucosa was associated with up-regulation of ICAM-1 and P-selectin and high levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed an intense staining in the inflamed colon. Biochemical methods and zymography were used to analyze MMP-9 and -2 activities in colon tissues from DNBS-injured rats. Treatment with teupolioside significantly reduced the appearance of diarrhoea and the loss of body weight. This was associated with a remarkable amelioration in the disruption of the colonic architecture and a significant reduction in colonic myeloperoxidase activity and malondialdehyde levels. Teupolioside also reduced the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PARP immunoreactivity in the colon and reduced the up-regulation of ICAM-1 and the expression of P-selectin. Therefore, teupolioside also reduced proMMP-9 and -2 activity induced in the colon by DNBS administration. The results of this study suggested that administration of teupolioside may be beneficial for treatment of inflammatory bowel disease.",
keywords = "Adhesion molecules, Colitis, MMP9 (matrix metallopeptidase 9), Teupolioside",
author = "{Di Paola}, Rosanna and Emanuela Esposito and Emanuela Mazzon and Luisa Riccardi and Rocco Caminiti and {Dal Toso}, Roberto and Giovanna Pressi and Salvatore Cuzzocrea",
year = "2009",
month = "3",
day = "1",
doi = "10.1016/j.bcp.2008.11.010",
language = "English",
volume = "77",
pages = "845--857",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis

AU - Di Paola, Rosanna

AU - Esposito, Emanuela

AU - Mazzon, Emanuela

AU - Riccardi, Luisa

AU - Caminiti, Rocco

AU - Dal Toso, Roberto

AU - Pressi, Giovanna

AU - Cuzzocrea, Salvatore

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The aim of the present study was to examine the effects of phenylpropanoid glycoside, teupolioside, biotechnologically produced by IRBN22 Ajuga reptans cell line, in rats subjected to experimental colitis. Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulfonic acid (DNBS). Teupolioside was administered daily orally (0.2 or 2 mg kg-1). On Day 4, animals were sacrificed and tissues were taken for histological and biochemical analysis. Four days after DNBS administration, colon TNF-α and IL-1β productions were increased, associated with colon damage. Neutrophil infiltration, by myeloperoxidase activity, in the mucosa was associated with up-regulation of ICAM-1 and P-selectin and high levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed an intense staining in the inflamed colon. Biochemical methods and zymography were used to analyze MMP-9 and -2 activities in colon tissues from DNBS-injured rats. Treatment with teupolioside significantly reduced the appearance of diarrhoea and the loss of body weight. This was associated with a remarkable amelioration in the disruption of the colonic architecture and a significant reduction in colonic myeloperoxidase activity and malondialdehyde levels. Teupolioside also reduced the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PARP immunoreactivity in the colon and reduced the up-regulation of ICAM-1 and the expression of P-selectin. Therefore, teupolioside also reduced proMMP-9 and -2 activity induced in the colon by DNBS administration. The results of this study suggested that administration of teupolioside may be beneficial for treatment of inflammatory bowel disease.

AB - The aim of the present study was to examine the effects of phenylpropanoid glycoside, teupolioside, biotechnologically produced by IRBN22 Ajuga reptans cell line, in rats subjected to experimental colitis. Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulfonic acid (DNBS). Teupolioside was administered daily orally (0.2 or 2 mg kg-1). On Day 4, animals were sacrificed and tissues were taken for histological and biochemical analysis. Four days after DNBS administration, colon TNF-α and IL-1β productions were increased, associated with colon damage. Neutrophil infiltration, by myeloperoxidase activity, in the mucosa was associated with up-regulation of ICAM-1 and P-selectin and high levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed an intense staining in the inflamed colon. Biochemical methods and zymography were used to analyze MMP-9 and -2 activities in colon tissues from DNBS-injured rats. Treatment with teupolioside significantly reduced the appearance of diarrhoea and the loss of body weight. This was associated with a remarkable amelioration in the disruption of the colonic architecture and a significant reduction in colonic myeloperoxidase activity and malondialdehyde levels. Teupolioside also reduced the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PARP immunoreactivity in the colon and reduced the up-regulation of ICAM-1 and the expression of P-selectin. Therefore, teupolioside also reduced proMMP-9 and -2 activity induced in the colon by DNBS administration. The results of this study suggested that administration of teupolioside may be beneficial for treatment of inflammatory bowel disease.

KW - Adhesion molecules

KW - Colitis

KW - MMP9 (matrix metallopeptidase 9)

KW - Teupolioside

UR - http://www.scopus.com/inward/record.url?scp=59749094375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59749094375&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2008.11.010

DO - 10.1016/j.bcp.2008.11.010

M3 - Article

C2 - 19070602

AN - SCOPUS:59749094375

VL - 77

SP - 845

EP - 857

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -